Amaia Malet-Larrea
Research Subjects
Amaia Malet-Larrea has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Estibaliz Goyenechea
Department of Physiology and Nutrition, University of Navarra, Pamplona, Spain
7 shared publications - Miguel Angel Gastelurrutia
Universidad de Granada
7 shared publications - Ainhoa Oñatibia-Astibia
Official Pharmacist Association of Gipuzkoa , Donostia/San Sebastián
4 shared publications - Shalom Isaac Benrimoj
Pharmaceutical Care Research Group. Faculty of Pharmacy. University of Granada, Granada, Spain; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing. University of Newcastle, Newcastle, Australia
4 shared publications Begoña Calvo
Pharmaceutical Technology Department, Faculty of Pharmacy, Universidad del País Vasco UPV/EHU, P. Universidad 7, 01006, Vitoria, Spain
3 shared publications- Alicia Rodríguez-Gascón
Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Lascaray Research Centre, University of the Basque Country EHU, Paseo de la Universidad n° 7, 01006 Vitoria-Gasteiz, Spain
2 shared publications
Latest Publications
- Open Access
- 18 February 2026
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 34 (5) , 625-631
Patients’ and community pharmacists’ perceptions of a new service for medicines subject to additional monitoring
Objectives: The perceptions of community pharmacists and patients regarding a new pharmaceutical service implemented in Gipuzkoa (Spain) aimed at improving medication adherence, safety, and understanding of medicines under additional monitoring for patients with chronic diseases were assessed. Methods: Twenty-seven community pharmacists and 145 patients in Gipuzkoa participated in the implementation of the new pharmacy service and self-administered questionnaires about their perceived satisfaction and overall evaluation were completed. Descriptive statistics were used to analyse the data. Key findings: High satisfaction with the service was reported by both patients and pharmacists (mean patients’ satisfaction score = 8.9/10; percentage of patients that positively rated the attention received from pharmacists = 97.7%). Better understanding and use of their medications was reported by 88.5%, >60.7% of the patients showed improved adherence and 84.6% felt more informed about side effects, indicating the service’s positive effect on medication knowledge and safety. The service was rated 8.7/10 by pharmacists; they reported improvements in patient adherence, quality of life, and medication knowledge. Nearly, all pharmacists observed enhanced reporting of adverse drug reaction integration into daily practice, with the role of the ‘practice change facilitator’ being emphasized as vital for successful implementation. Conclusions: The service was positively evaluated by community pharmacists and patients for enhancing medication management and patient outcomes. Expanding this service could lead to improvements in the quality of pharmaceutical care and patient safety from the stakeholders’ perspective. Future efforts should focus on refining training, support, and integration into routine healthcare practice to ensure sustained success.
- 18 February 2026
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 34 (5) , 625-631
Open AccessPatients’ and community pharmacists’ perceptions of a new service for medicines subject to additional monitoring
Objectives: The perceptions of community pharmacists and patients regarding a new pharmaceutical service implemented in Gipuzkoa (Spain) aimed at improving medication adherence, safety, and understanding of medicines under additional monitoring for patients with chronic diseases were assessed. Methods: Twenty-seven community pharmacists and 145 patients in Gipuzkoa participated in the implementation of the new pharmacy service and self-administered questionnaires about their perceived satisfaction and overall evaluation were completed. Descriptive statistics were used to analyse the data. Key findings: High satisfaction with the service was reported by both patients and pharmacists (mean patients’ satisfaction score = 8.9/10; percentage of patients that positively rated the attention received from pharmacists = 97.7%). Better understanding and use of their medications was reported by 88.5%, >60.7% of the patients showed improved adherence and 84.6% felt more informed about side effects, indicating the service’s positive effect on medication knowledge and safety. The service was rated 8.7/10 by pharmacists; they reported improvements in patient adherence, quality of life, and medication knowledge. Nearly, all pharmacists observed enhanced reporting of adverse drug reaction integration into daily practice, with the role of the ‘practice change facilitator’ being emphasized as vital for successful implementation. Conclusions: The service was positively evaluated by community pharmacists and patients for enhancing medication management and patient outcomes. Expanding this service could lead to improvements in the quality of pharmaceutical care and patient safety from the stakeholders’ perspective. Future efforts should focus on refining training, support, and integration into routine healthcare practice to ensure sustained success.
- Open Access
- 15 August 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (9) , e70201
Impact of Additional Monitoring on Pharmacovigilance and Pharmacists' Role: A Scoping Review
Introduction: Pharmacovigilance plays a critical role in ensuring the safety of medicinal products, particularly those under additional monitoring (AM). The European Union (EU) implemented AM in 2012 to enhance post‐marketing surveillance. However, its impact on adverse drug reaction (ADR) reporting and pharmacists' role remains insufficiently explored. This scoping review examines the influence of AM label on ADR reporting management, and pharmacists' awareness and involvement in AM medicines. Methods: A systematic search across four scientific databases (Web of Science, Scopus, Science Direct, and PubMed) and gray literature sources, covering studies published between 2012 and 2024 in the EU, identified 17 relevant studies according to eligibility criteria: AM labeling's impact on pharmacovigilance in the EU. Relevant data (title, year of publication, country, field, design, objective, results) and relation with research questions were charted. Results: AM label alone does not significantly increase ADR reporting rates. However, structured training programs and targeted interventions for healthcare professionals (HCPs), particularly pharmacists, lead to improved ADR reporting and patient safety outcomes. Pharmacists exhibit the highest awareness of AM among HCPs but often underutilize their role in ADR reporting. Different studies demonstrated that pharmacist‐led interventions significantly increased ADR notifications. Education campaigns, standardized reporting protocols, and enhanced integration of AM into clinical practice can strengthen AM pharmacovigilance efforts. Conclusions: This review highlights the need to implement structured AM training programs and develop systematic evaluation frameworks to assess the effectiveness of AM labeling in improving pharmacovigilance practices. Further research is required to optimize AM strategies and reinforce pharmacists' role in post‐marketing drug safety.
- 15 August 2025
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 34 (9) , e70201
Open AccessImpact of Additional Monitoring on Pharmacovigilance and Pharmacists' Role: A Scoping Review
Introduction: Pharmacovigilance plays a critical role in ensuring the safety of medicinal products, particularly those under additional monitoring (AM). The European Union (EU) implemented AM in 2012 to enhance post‐marketing surveillance. However, its impact on adverse drug reaction (ADR) reporting and pharmacists' role remains insufficiently explored. This scoping review examines the influence of AM label on ADR reporting management, and pharmacists' awareness and involvement in AM medicines. Methods: A systematic search across four scientific databases (Web of Science, Scopus, Science Direct, and PubMed) and gray literature sources, covering studies published between 2012 and 2024 in the EU, identified 17 relevant studies according to eligibility criteria: AM labeling's impact on pharmacovigilance in the EU. Relevant data (title, year of publication, country, field, design, objective, results) and relation with research questions were charted. Results: AM label alone does not significantly increase ADR reporting rates. However, structured training programs and targeted interventions for healthcare professionals (HCPs), particularly pharmacists, lead to improved ADR reporting and patient safety outcomes. Pharmacists exhibit the highest awareness of AM among HCPs but often underutilize their role in ADR reporting. Different studies demonstrated that pharmacist‐led interventions significantly increased ADR notifications. Education campaigns, standardized reporting protocols, and enhanced integration of AM into clinical practice can strengthen AM pharmacovigilance efforts. Conclusions: This review highlights the need to implement structured AM training programs and develop systematic evaluation frameworks to assess the effectiveness of AM labeling in improving pharmacovigilance practices. Further research is required to optimize AM strategies and reinforce pharmacists' role in post‐marketing drug safety.
- Open Access
- 1 October 2021
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 15, 2363-2376
Cost–Utility Analysis of a Medication Adherence Management Service Alongside a Cluster Randomized Control Trial in Community Pharmacy
Background: It is necessary to determine the cost utility of adherence interventions in chronic diseases due to humanistic and economic burden of non-adherence. Purpose: To evaluate, alongside a cluster-randomized controlled trial, the cost-utility of a pharmacist-led medication adherence management service (MAMS) compared with usual care in community pharmacies. Materials and Methods: The trial was conducted over six months. Patients with treatments for hypertension, asthma or chronic obstructive pulmonary disease (COPD) were included. Patients in the intervention group (IG) received a MAMS based on a brief complex intervention, whilst patients in the control group (CG) received usual care. The cost–utility analysis adopted a health system perspective. Costs related to medications, healthcare resources and adherence intervention were included. The effectiveness was estimated as quality-adjusted life years (QALYs), using a multiple imputation missing data model. The incremental cost–utility ratio (ICUR) was calculated on the total sample of patients. Results: A total of 1186 patients were enrolled (IG: 633; CG: 553). The total intervention cost was estimated to be € 27.33 ± 0.43 per patient for six months. There was no statistically significant difference in total cost of medications and healthcare resources per patient between IG and CG. The values of EQ-5D-5L at 6 months were significantly higher in the IG [IG: 0.881 ± 0.005 vs CG: 0.833 ± 0.006; p = 0.000]. In the base case, the service was more expensive and more effective than usual care, resulting in an ICUR of € 1,494.82/QALY. In the complete case, the service resulted in an ICUR of € 2,086.30/QALY, positioned between the north-east and south-east quadrants of the cost–utility plane. Using a threshold value of € 20,000/QALY gained, there is a 99% probability that the intervention is cost-effective. Conclusion: The medication adherence management service resulted in an improvement in the quality of life of the population with chronic disease, with similar costs compared to usual care. The service is cost-effective.
- 1 October 2021
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 15, 2363-2376
Open AccessCost–Utility Analysis of a Medication Adherence Management Service Alongside a Cluster Randomized Control Trial in Community Pharmacy
Background: It is necessary to determine the cost utility of adherence interventions in chronic diseases due to humanistic and economic burden of non-adherence. Purpose: To evaluate, alongside a cluster-randomized controlled trial, the cost-utility of a pharmacist-led medication adherence management service (MAMS) compared with usual care in community pharmacies. Materials and Methods: The trial was conducted over six months. Patients with treatments for hypertension, asthma or chronic obstructive pulmonary disease (COPD) were included. Patients in the intervention group (IG) received a MAMS based on a brief complex intervention, whilst patients in the control group (CG) received usual care. The cost–utility analysis adopted a health system perspective. Costs related to medications, healthcare resources and adherence intervention were included. The effectiveness was estimated as quality-adjusted life years (QALYs), using a multiple imputation missing data model. The incremental cost–utility ratio (ICUR) was calculated on the total sample of patients. Results: A total of 1186 patients were enrolled (IG: 633; CG: 553). The total intervention cost was estimated to be € 27.33 ± 0.43 per patient for six months. There was no statistically significant difference in total cost of medications and healthcare resources per patient between IG and CG. The values of EQ-5D-5L at 6 months were significantly higher in the IG [IG: 0.881 ± 0.005 vs CG: 0.833 ± 0.006; p = 0.000]. In the base case, the service was more expensive and more effective than usual care, resulting in an ICUR of € 1,494.82/QALY. In the complete case, the service resulted in an ICUR of € 2,086.30/QALY, positioned between the north-east and south-east quadrants of the cost–utility plane. Using a threshold value of € 20,000/QALY gained, there is a 99% probability that the intervention is cost-effective. Conclusion: The medication adherence management service resulted in an improvement in the quality of life of the population with chronic disease, with similar costs compared to usual care. The service is cost-effective.
- 16 April 2020
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 42 (2) , 331-335
Effect of health professional intervention on adherence to statin use according to the cause of patient non-adherence
Background Non-adherence is a problem that particularly affects those with chronic diseases. Studying causes for not following the treatment is necessary to choose the best intervention to improve non-adherence. Objective Analyze how the intentionality of non-adherence modulates the effects of professional intervention in patients with hypercholesterolemia. Setting: Community pharmacies and primary care centres in Spain. Methods A 6-month randomized controlled trial was conducted in 46 community pharmacies and 50 primary care centres in Spain. Adherence to statin therapy was measured with the Morisky-Green-Levine test. Non-adherence was classified based on the intentionality. Results 746 Patients were recruited for the study (465 non-adherent and 281 adherent). Of those, 237 were randomly assigned to the intervention group and 228 to the non-intervention group. The 56.5% of non-adherent patients were classified as unintentional non-adherents and 43.5% as intentional non-adherents. More patients in the intervention group finished being adherent compared with the non-intervention group (+ 17.2% for intentional non-adherents and + 27.4% for unintentional non-adherence). The percentage of patients in the intervention group who completed the study as adherent was higher among those who previously had unintentional non-adherence (66.4%) compared to those with intentional non- adherence (55.3%) (p < 0.001). Conclusion Intervention provided to patients with unintentional non-adherence was more effective than intervention provided to patients with intentional non- adherence.
- 16 April 2020
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 42 (2) , 331-335
Effect of health professional intervention on adherence to statin use according to the cause of patient non-adherence
Background Non-adherence is a problem that particularly affects those with chronic diseases. Studying causes for not following the treatment is necessary to choose the best intervention to improve non-adherence. Objective Analyze how the intentionality of non-adherence modulates the effects of professional intervention in patients with hypercholesterolemia. Setting: Community pharmacies and primary care centres in Spain. Methods A 6-month randomized controlled trial was conducted in 46 community pharmacies and 50 primary care centres in Spain. Adherence to statin therapy was measured with the Morisky-Green-Levine test. Non-adherence was classified based on the intentionality. Results 746 Patients were recruited for the study (465 non-adherent and 281 adherent). Of those, 237 were randomly assigned to the intervention group and 228 to the non-intervention group. The 56.5% of non-adherent patients were classified as unintentional non-adherents and 43.5% as intentional non-adherents. More patients in the intervention group finished being adherent compared with the non-intervention group (+ 17.2% for intentional non-adherents and + 27.4% for unintentional non-adherence). The percentage of patients in the intervention group who completed the study as adherent was higher among those who previously had unintentional non-adherence (66.4%) compared to those with intentional non- adherence (55.3%) (p < 0.001). Conclusion Intervention provided to patients with unintentional non-adherence was more effective than intervention provided to patients with intentional non- adherence.
- 24 April 2018
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 27 (1) , 25-33
Defining and characterising age-friendly community pharmacies: a qualitative study
Introduction: The Global Network of Age-friendly Cities is a project promoted by the World Health Organization as a response to demographic ageing and urbanization process. San Sebastian, Spain, is one of these Age-friendly Cities and community pharmacies of the city joined the initiative.Objective: To define and implement the Age-friendly Pharmacy concept to promote active ageing, optimize the contribution of community pharmacies of San Sebastian to the friendliness of the city and to the improvement of quality of life of the ageing population.Method: A bottom-up participative approach was undertaken. A focus group was conducted to determine elderly people’s opinions and expectations of community pharmacy. The information obtained was analysed using content analysis and validated for reliability, usefulness and applicability through three expert groups of community pharmacy owners and staff.Key findings: Fifteen requirements were agreed, covering four main areas: relationships, pharmacy layout, pharmaceutical services and communication of services. Initially, 18 community pharmacies committed to become Age-friendly Pharmacies by pledging to these requirements and the Official Pharmacist Association of Gipuzkoa supported pharmacies in the implementation of the initiative.Conclusion: This study suggests that there is demand for a patient-centred community pharmacy to support older people, in which pharmaceutical care services are required. The 18 Age-friendly Pharmacies together with the Official Pharmacist Association of Gipuzkoa have publicly committed to actively work on social and patient-centred care to meet the needs of the ageing population.
- 24 April 2018
- Published by Oxford University Press (OUP) in International Journal of Pharmacy Practice
- Vol. 27 (1) , 25-33
Defining and characterising age-friendly community pharmacies: a qualitative study
Introduction: The Global Network of Age-friendly Cities is a project promoted by the World Health Organization as a response to demographic ageing and urbanization process. San Sebastian, Spain, is one of these Age-friendly Cities and community pharmacies of the city joined the initiative.Objective: To define and implement the Age-friendly Pharmacy concept to promote active ageing, optimize the contribution of community pharmacies of San Sebastian to the friendliness of the city and to the improvement of quality of life of the ageing population.Method: A bottom-up participative approach was undertaken. A focus group was conducted to determine elderly people’s opinions and expectations of community pharmacy. The information obtained was analysed using content analysis and validated for reliability, usefulness and applicability through three expert groups of community pharmacy owners and staff.Key findings: Fifteen requirements were agreed, covering four main areas: relationships, pharmacy layout, pharmaceutical services and communication of services. Initially, 18 community pharmacies committed to become Age-friendly Pharmacies by pledging to these requirements and the Official Pharmacist Association of Gipuzkoa supported pharmacies in the implementation of the initiative.Conclusion: This study suggests that there is demand for a patient-centred community pharmacy to support older people, in which pharmaceutical care services are required. The 18 Age-friendly Pharmacies together with the Official Pharmacist Association of Gipuzkoa have publicly committed to actively work on social and patient-centred care to meet the needs of the ageing population.
- 2 December 2016
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 18 (9) , 1069-1078
Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients
Background Drug related problems have a significant clinical and economic burden on patients and the healthcare system. Medication review with follow-up (MRF) is a professional pharmacy service aimed at improving patient’s health outcomes through an optimization of the medication. Objective To ascertain the economic impact of the MRF service provided in community pharmacies to aged polypharmacy patients comparing MRF with usual care, by undertaking a cost analysis and a cost-benefit analysis. Methods The economic evaluation was based on a cluster randomized controlled trial. Patients in the intervention group (IG) received the MRF service and the comparison group (CG) received usual care. The analysis was conducted from the national health system (NHS) perspective over 6 months. Direct medical costs were included and expressed in euros at 2014 prices. Health benefits were estimated by assigning a monetary value to the quality-adjusted life years. One-way deterministic sensitivity analysis was undertaken in order to analyse the uncertainty. Results The analysis included 1403 patients (IG: n = 688 vs CG: n = 715). The cost analysis showed that the MRF saved 97 € per patient in 6 months. Extrapolating data to 1 year and assuming a fee for service of 22 € per patient-month, the estimated savings were 273 € per patient-year. The cost-benefit ratio revealed that for every 1 € invested in MRF, a benefit of 3.3 € to 6.2 € was obtained. Conclusion The MRF provided health benefits to patients and substantial cost savings to the NHS. Investment in this service would represent an efficient use of healthcare resources.
- 2 December 2016
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 18 (9) , 1069-1078
Cost analysis and cost-benefit analysis of a medication review with follow-up service in aged polypharmacy patients
Background Drug related problems have a significant clinical and economic burden on patients and the healthcare system. Medication review with follow-up (MRF) is a professional pharmacy service aimed at improving patient’s health outcomes through an optimization of the medication. Objective To ascertain the economic impact of the MRF service provided in community pharmacies to aged polypharmacy patients comparing MRF with usual care, by undertaking a cost analysis and a cost-benefit analysis. Methods The economic evaluation was based on a cluster randomized controlled trial. Patients in the intervention group (IG) received the MRF service and the comparison group (CG) received usual care. The analysis was conducted from the national health system (NHS) perspective over 6 months. Direct medical costs were included and expressed in euros at 2014 prices. Health benefits were estimated by assigning a monetary value to the quality-adjusted life years. One-way deterministic sensitivity analysis was undertaken in order to analyse the uncertainty. Results The analysis included 1403 patients (IG: n = 688 vs CG: n = 715). The cost analysis showed that the MRF saved 97 € per patient in 6 months. Extrapolating data to 1 year and assuming a fee for service of 22 € per patient-month, the estimated savings were 273 € per patient-year. The cost-benefit ratio revealed that for every 1 € invested in MRF, a benefit of 3.3 € to 6.2 € was obtained. Conclusion The MRF provided health benefits to patients and substantial cost savings to the NHS. Investment in this service would represent an efficient use of healthcare resources.
- 1 November 2016
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 16 (6) , 747-758
Cost-effectiveness of professional pharmacy services in community pharmacy: a systematic review
Introduction: The aim was to determine whether professional pharmacy services (PPS) provided to ambulatory patients attending community pharmacy are cost-effective compared with usual care (UC). Areas covered: MEDLINE, Web of Knowledge, Scopus, Cochrane Library and Centre for Reviews and Dissemination databases were searched, and the risk of bias of randomized controlled trials, and the methodological quality of economic evaluations was assessed. A total of 17 economic evaluations of 13 studies were included. Seven studies were classified as high-, three as medium- and three as low-quality. PPS were more effective and less costly than UC in four studies; seven studies concluded that PPS were more effective and more costly and two studies concluded that the service was as effective as the UC, with higher and lower costs. Expert commentary: Although the uncertainty was variable among the studies, a general trend towards the cost-effectiveness of PPS was observed. Decision makers are encouraged to consider the feasibility of implementing PPS.
- 1 November 2016
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 16 (6) , 747-758
Cost-effectiveness of professional pharmacy services in community pharmacy: a systematic review
Introduction: The aim was to determine whether professional pharmacy services (PPS) provided to ambulatory patients attending community pharmacy are cost-effective compared with usual care (UC). Areas covered: MEDLINE, Web of Knowledge, Scopus, Cochrane Library and Centre for Reviews and Dissemination databases were searched, and the risk of bias of randomized controlled trials, and the methodological quality of economic evaluations was assessed. A total of 17 economic evaluations of 13 studies were included. Seven studies were classified as high-, three as medium- and three as low-quality. PPS were more effective and less costly than UC in four studies; seven studies concluded that PPS were more effective and more costly and two studies concluded that the service was as effective as the UC, with higher and lower costs. Expert commentary: Although the uncertainty was variable among the studies, a general trend towards the cost-effectiveness of PPS was observed. Decision makers are encouraged to consider the feasibility of implementing PPS.
- 9 June 2016
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 82 (3) , 831-838
The impact of a medication review with follow‐up service on hospital admissions in aged polypharmacy patients
Aims: The aims were to assess the impact of a medication review with follow‐up (MRF) service provided in community pharmacy to aged polypharmacy patients on the number of medication‐related hospital admissions and to estimate the effect on hospital costs.Methods: This was a sub‐analysis of a cluster randomized controlled trials carried out in 178 community pharmacies in Spain. Pharmacies in the intervention group (IG) provided a comprehensive medication review during 6 months. Pharmacists in the comparison group (CG) delivered usual care. For the purposes of this sub‐analysis, an expert panel of three internal medicine specialists screened the hospitalizations occurring during the main study, in order to identify medication‐related hospitalizations. Inter‐rater reliability was measured using Fleiss's kappa. Hospital costs were calculated using diagnosis related groups.Results: One thousand four hundred and three patients were included in the main study and they had 83 hospitalizations. Forty‐two hospitalizations (50.6%) were medicine‐related, with a substantial level of agreement among the experts (kappa = 0.65, 95% CI 0.52, 0.78, P < 0.01). The number of medication‐related hospitalizations was significantly lower in patients receiving MRF (IG 11, GC 31, P = 0.042). The probability of being hospitalized was 3.7 times higher in the CG (odds ratio 3.7, 95% CI 1.2, 11.3, P = 0.021). Costs for a medicine‐related hospitalization were €6672. Medication‐related hospitalization costs were lower for patients receiving MRF [IG: €94 (SD 917); CG: €301 (SD 2102); 95% CI 35.9, 378.0, P = 0.018].Conclusion: MRF provided by community pharmacists might be an effective strategy to balance the assurance of the benefit from medications and the avoidance of medication‐related hospitalizations in aged patients using polypharmacy.
- 9 June 2016
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 82 (3) , 831-838
The impact of a medication review with follow‐up service on hospital admissions in aged polypharmacy patients
Aims: The aims were to assess the impact of a medication review with follow‐up (MRF) service provided in community pharmacy to aged polypharmacy patients on the number of medication‐related hospital admissions and to estimate the effect on hospital costs.Methods: This was a sub‐analysis of a cluster randomized controlled trials carried out in 178 community pharmacies in Spain. Pharmacies in the intervention group (IG) provided a comprehensive medication review during 6 months. Pharmacists in the comparison group (CG) delivered usual care. For the purposes of this sub‐analysis, an expert panel of three internal medicine specialists screened the hospitalizations occurring during the main study, in order to identify medication‐related hospitalizations. Inter‐rater reliability was measured using Fleiss's kappa. Hospital costs were calculated using diagnosis related groups.Results: One thousand four hundred and three patients were included in the main study and they had 83 hospitalizations. Forty‐two hospitalizations (50.6%) were medicine‐related, with a substantial level of agreement among the experts (kappa = 0.65, 95% CI 0.52, 0.78, P < 0.01). The number of medication‐related hospitalizations was significantly lower in patients receiving MRF (IG 11, GC 31, P = 0.042). The probability of being hospitalized was 3.7 times higher in the CG (odds ratio 3.7, 95% CI 1.2, 11.3, P = 0.021). Costs for a medicine‐related hospitalization were €6672. Medication‐related hospitalization costs were lower for patients receiving MRF [IG: €94 (SD 917); CG: €301 (SD 2102); 95% CI 35.9, 378.0, P = 0.018].Conclusion: MRF provided by community pharmacists might be an effective strategy to balance the assurance of the benefit from medications and the avoidance of medication‐related hospitalizations in aged patients using polypharmacy.
- 1 November 2014
- Published by Elsevier in Value in Health
- Vol. 17 (7) , A511-A512
Cost-Utility Analysis of A Medication Review With Follow-Up for Older People With Polypharmacy in Community Pharmacies in Spain: Consigue Program
- 1 November 2014
- Published by Elsevier in Value in Health
- Vol. 17 (7) , A511-A512
Cost-Utility Analysis of A Medication Review With Follow-Up for Older People With Polypharmacy in Community Pharmacies in Spain: Consigue Program